Original Source(s)
Related Content
FDA Expands Gene Therapy for Younger Patients
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
July 2, 2026
-
3 min
HHS Seeks Broader Access to Health Data
"We can’t do anything our agreements don’t allow us to do"
June 4, 2026
-
12 min
Novel LIFR Variant Identified in Stuve-Wiedemann Syndrome
Case report highlights the role of early genetic confirmation in severe skeletal dysplasia
by Henry Thomas
February 10, 2026
-
2 min